Double KL; Gerlach M; Youdim MBH; Riederer P, 2000, 'Impaired iron homeostasis in Parkinson's disease', in Journal of Neural Transmission, Supplement, pp. 37 - 58

Harper C; Sheedy D; Halliday GM; Double KL; Dodd P; Lowehl JM; Kril J, 1998, 'Neuropathological studies: the relationship between alcohol and ageing', in NIAAA Research monograph 33: Alcohol Problems and Aging, edn. Original, US Department of Health and Human Services, Bethesda, MD USA, pp. 117 - 134

Tan B; Double KL; Burne J; Diong J, 2016, 'Tension-referenced measures of gastrocnemius slack length and stiffness in Parkinson's disease', Movement Disorders, vol. 31, pp. 1914 - 1918, http://dx.doi.org/10.1002/mds.26530

Davies KM; Mercer JFB; Chen N; Double KL, 2016, 'Copper dyshomoeostasis in Parkinson's disease: Implications for pathogenesis and indications for novel therapeutics', Clinical Science, vol. 130, pp. 565 - 574, http://dx.doi.org/10.1042/CS20150153

Schroeder RL; Double KL; Gerber JP, 2015, 'Using Sepia melanin as a PD model to describe the binding characteristics of neuromelanin - A critical review', Journal of Chemical Neuroanatomy, vol. 64-65, pp. 20 - 32, http://dx.doi.org/10.1016/j.jchemneu.2015.02.001

Davies KM; Hare DJ; Bohic S; James SA; Billings JL; Finkelstein DI; Doble PA; Double KL, 2015, 'Comparative Study of Metal Quantification in Neurological Tissue Using Laser Ablation-Inductively Coupled Plasma-Mass Spectrometry Imaging and X-ray Fluorescence Microscopy', Analytical Chemistry, vol. 87, pp. 6639 - 6645, http://dx.doi.org/10.1021/acs.analchem.5b01454

Purves-Tyson TD; Boerrigter D; Allen K; Zavitsanou K; Karl T; Djunaidi V; Double KL; Desai R; Handelsman DJ; Weickert CS, 2015, 'Testosterone attenuates and the selective estrogen receptor modulator, raloxifene, potentiates amphetamine-induced locomotion in male rats', Hormones and Behavior, vol. 70, pp. 73 - 84, http://dx.doi.org/10.1016/j.yhbeh.2015.02.005

Todd G; Haberfield M; Faulkner PL; Rae C; Hayes M; Wilcox RA; Taylor JL; Gandevia SC; Godau J; Berg D, 2014, 'Hand function is impaired in healthy older adults at risk of Parkinson’s disease', Journal of Neural Transmission, vol. 121, pp. 1377 - 1386, http://dx.doi.org/10.1007/s00702-014-1218-y

Todd G; Haberfield M; Faulkner PL; Hayes M; Wilcox RA; Rae C; Bulathsinhala T; Grunstein RR; Yee BJ; Double KL, 2014, 'Upper limb function is normal in patients with restless legs syndrome (Willis-Ekbom Disease)', Clinical Neurophysiology, http://dx.doi.org/10.1016/j.clinph.2014.07.010

Purves-Tyson TD; Owens SJ; Double KL; Desai R; Handelsman DJ; Weickert CS, 2014, 'Testosterone induces molecular changes in dopamine signaling pathway molecules in the adolescent male rat nigrostriatal pathway', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0091151

Davies KM; Bohic S; Carmona A; Ortega R; Cottam V; Hare DJ; Finberg JPM; Reyes S; Halliday GM; Mercer JFB, 2014, 'Copper pathology in vulnerable brain regions in Parkinson's disease', Neurobiology of Aging, vol. 35, pp. 858 - 866, http://dx.doi.org/10.1016/j.neurobiolaging.2013.09.034

Reyes S; Cottam V; Kirik D; Double KL; Halliday GM, 2013, 'Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra', Movement Disorders, vol. 28, pp. 1351 - 1359, http://dx.doi.org/10.1002/mds.25493

Dang TNT; Dobson-Stone C; Glaros EN; Kim WS; Hallupp M; Bartley L; Piguet O; Hodges JR; Halliday GM; Double KL, 2013, 'Endogenous progesterone levels and frontotemporal dementia: Modulation of TDP-43 and Tau levels in vitro and treatment of the A315T TARDBP mouse model', DMM Disease Models and Mechanisms, vol. 6, pp. 1198 - 1204, http://dx.doi.org/10.1242/dmm.011460

Davies KM; Hare DJ; Cottam V; Chen N; Hilgers L; Halliday G; Mercer JFB; Double KL, 2013, 'Localization of copper and copper transporters in the human brain', Metallomics, vol. 5, pp. 43 - 51, http://dx.doi.org/10.1039/c2mt20151h

Reyes S; Fu Y; Double KL; Cottam V; Thompson LH; Kirik D; Paxinos G; Watson C; Cooper HM; Halliday GM, 2013, 'Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease', Neurobiology of Aging, vol. 34, pp. 873 - 886, http://dx.doi.org/10.1016/j.neurobiolaging.2012.07.019

Double KL, 2012, 'Neuronal vulnerability in Parkinson's disease', Parkinsonism and Related Disorders, vol. 18

Purves-Tyson TD; Handelsman DJ; Double KL; Owens SJ; Bustamante S; Weickert CS, 2012, 'Testosterone regulation of sex steroid-related mRNAs and dopamine-related mRNAs in adolescent male rat substantia nigra', BMC Neuroscience, vol. 13, http://dx.doi.org/10.1186/1471-2202-13-95

Reyes S; Fu Y; Double K; Thompson L; Kirik D; Paxinos G; Halliday GM, 2012, 'GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area', Journal of Comparative Neurology, vol. 520, pp. 2591 - 2607, http://dx.doi.org/10.1002/cne.23051

Chan SW; Dunlop RA; Rowe A; Double KL; Rodgers KJ, 2012, 'L-DOPA is incorporated into brain proteins of patients treated for Parkinson's disease, inducing toxicity in human neuroblastoma cells in vitro', Experimental Neurology, vol. 238, pp. 29 - 37, http://dx.doi.org/10.1016/j.expneurol.2011.09.029

Double KL, 2012, 'Neuronal vulnerability in Parkinson's disease', Parkinsonism and Related Disorders, vol. 18, pp. 52 - 54

Double KL; Todd G; Duma SR, 2010, 'Pathophysiology of transcranial sonography signal changes in the human substantia Nigra', International Review of Neurobiology, vol. 90, pp. 107 - 120, http://dx.doi.org/10.1016/S0074-7742(10)90008-1

Kurz A; Double KL; Lastres-Becker I; Tozzi A; Tantucci M; Bockhart V; Bonin M; García-Arencibia M; Nuber S; Schlaudraff F, 2010, 'A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice', PLoS ONE, vol. 5, pp. 1 - 15, http://dx.doi.org/10.1371/journal.pone.0011464

Double KL; Halliday GM; Dunkley PR; Dickson PW; Gerlach M; Riederer P, 2010, 'Pigmentation in the human brain and risk of Parkinson's disease', Annals of Neurology, vol. 67, pp. 553 - 554, http://dx.doi.org/10.1002/ana.21882

Double DL; Reyes R; Werry WL; Halliday HM, 2010, 'Selective cell death in neurodegeneration: Why are some neurons spared in vulnerable regions?', Progress in Neurobiology, vol. 92, pp. 316 - 329, http://dx.doi.org/10.1016/j.pneurobio.2010.06.001

Schofield EC; Halliday GM; Kwok J; Loy C; Double KL; Hodges JR, 2010, 'Low serum progranulin predicts the presence of mutations: A prospective study', Journal of Alzheimer's Disease, vol. 22, pp. 981 - 984, http://dx.doi.org/10.3233/JAD-2010-101032

Todd G; Taylor JL; Baumann D; Butler JE; Duma SR; Hayes M; Carew-Jones F; Piguet O; Behnke S; Ridding MC, 2010, 'Substantia nigra echomorphology and motor cortex excitability', NeuroImage, vol. 50, pp. 1351 - 1356, http://dx.doi.org/10.1016/j.neuroimage.2010.01.088

Piguet O; Double KL; Kril JJ; Harasty J; Macdonald V; McRitchie DA; Halliday GM, 2009, 'White matter loss in healthy ageing: A postmortem analysis', Neurobiology of Aging, vol. 30, pp. 1288 - 1295, http://dx.doi.org/10.1016/j.neurobiolaging.2007.10.015

Double KL; Rowe DB; Carew-Jones FM; Hayes M; Chan DKY; Blackie J; Corbett A; Joffe R; Fung VS; Morris J, 2009, 'Anti-melanin antibodies are increased in sera in Parkinson's disease', Experimental Neurology, vol. 217, pp. 297 - 301, http://dx.doi.org/10.1016/j.expneurol.2009.03.002

Bohic S; Murphy K; Paulus W; Cloetens P; Salomé M; Susini J; Double K, 2008, 'Intracellular chemical imaging of the developmental phases of human neuromelanin using synchrotron X-ray microspectroscopy', Analytical Chemistry, vol. 80, pp. 9557 - 9566, http://dx.doi.org/10.1021/ac801817k

Double KL; Dedov VN; Fedorow H; Kettle E; Halliday GM; Garner B; Brunk UT, 2008, 'The comparative biology of neuromelanin and lipofuscin in the human brain', Cellular and Molecular Life Sciences, vol. 65, pp. 1669 - 1682, http://dx.doi.org/10.1007/s00018-008-7581-9

Gerlach M; Riederer P; Double KL, 2008, 'Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease', Parkinsonism and Related Disorders, vol. 14, http://dx.doi.org/10.1016/j.parkreldis.2008.04.028

Sutherland G; Mellick G; Newman J; Double KL; Stevens J; Lee L; Rowe D; Silburn P; Halliday GM, 2008, 'Haplotype analysis of the IGF2-INS-TH gene cluster in Parkinson's disease', American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, vol. 147, pp. 495 - 499, http://dx.doi.org/10.1002/ajmg.b.30633

Behnke S; Double KL; Duma S; Broe GA; Guenther V; Becker G; Halliday GM, 2007, 'Substantia nigra echomorphology in the healthy very old: Correlation with motor slowing', NeuroImage, vol. 34, pp. 1054 - 1059, http://dx.doi.org/10.1016/j.neuroimage.2006.10.010

Dedov VN; Griffiths FM; Garner B; Halliday GM; Double KL, 2007, 'Lipid content determines aggregation of neuromelanin granules in vitro', Journal of Neural Transmission, Supplementa, pp. 35 - 38, http://dx.doi.org/10.1007/978-3-211-73574-9-5

Youdim MBH; Double KL; Gerlach M; Riederer P, 2006, 'Preface - Special issue: Neuromelanin', Journal of Neural Transmission, vol. 113, pp. 717 - 719, http://dx.doi.org/10.1007/s00702-006-0520-8

Tribl F; Riederer P; Double KL; Gerlach M, 2006, 'Neuromelanin, a pigment with unknown function', Neuroforum, vol. 12, pp. 190 - 196

Double KL, 2006, 'Functional effects of neuromelanin and synthetic melanin in model systems', Journal of Neural Transmission, vol. 113, pp. 751 - 756, http://dx.doi.org/10.1007/s00702-006-0450-5

Double KL; Halliday GM, 2006, 'New face of neuromelanin', Journal of Neural Transmission, Supplement, pp. 119 - 123

Fedorow H; Halliday GM; Rickert CH; Gerlach M; Riederer P; Double KL, 2006, 'Evidence for specific phases in the development of human neuromelanin', Neurobiology of Aging, vol. 27, pp. 506 - 512, http://dx.doi.org/10.1016/j.neurobiolaging.2005.02.015

Halliday GM; Fedorow H; Rickert CH; Gerlach M; Riederer P; Double KL, 2006, 'Evidence for specific phases in the development of human neuromelanin', Journal of Neural Transmission, vol. 113, pp. 721 - 728, http://dx.doi.org/10.1007/s00702-006-0449-y

Fedorow H; Pickford R; Kettle E; Cartwright M; Halliday GM; Gerlach M; Riederer P; Garner B; Double KL, 2006, 'Investigation of the lipid component of neuromelanin', Journal of Neural Transmission, vol. 113, pp. 735 - 739, http://dx.doi.org/10.1007/s00702-006-0451-4

Tribl F; Riederer P; Double KL; Gerlach M, 2006, 'Neuromelanin, ein Pigment mit unbekannter Function', Neuroforum, vol. 2, pp. 188 - 194

Fedorow H; Tribl F; Halliday G; Gerlach M; Riederer P; Double KL, 2005, 'Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease', Progress in Neurobiology, vol. 75, pp. 109 - 124, http://dx.doi.org/10.1016/j.pneurobio.2005.02.001

Li J; Scheller C; Koutsilieri E; Griffiths F; Beart PM; Mercer LD; Halliday G; Kettle E; Rowe D; Riederer P, 2005, 'Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells', Journal of Neurochemistry, vol. 95, pp. 599 - 608, http://dx.doi.org/10.1111/j.1471-4159.2005.03404.x

Fedorow H; Pickford R; Hook JM; Double KL; Halliday GM; Gerlach M; Riederer P; Garner B, 2005, 'Dolichol is the major lipid component of human substantia nigra neuromelanin', Journal of Neurochemistry, vol. 92, pp. 990 - 995, http://dx.doi.org/10.1111/j.1471-4159.2004.02975.x

Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL, 2005, 'α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease', Brain, vol. 128, pp. 2654 - 2664, http://dx.doi.org/10.1093/brain/awh584

Foley P; Gerlach M; Double KL; Riederer P, 2004, 'Dopamine receptor agonists in the therapy of Parkinson's disease', Journal of Neural Transmission, vol. 111, pp. 1375 - 1446, http://dx.doi.org/10.1007/s00702-003-0059-x

Gotz ME; Double KL; Gerlach M; Youdim MB; Riederer P, 2004, 'The relevance of iron in the pathogenesis of Parkinson`s disease', Annals of the New York Academy of Sciences, vol. 1012, pp. 193 - 208

Double KL; Gerlach M; Schünemann V; Trautwein AX; Zecca L; Gallorini M; Youdim MBH; Riederer P; Ben-Shachar D, 2003, 'Iron-binding characteristics of neuromelanin of the human substantia nigra', Biochemical Pharmacology, vol. 66, pp. 489 - 494, http://dx.doi.org/10.1016/S0006-2952(03)00293-4

Double KL; Halliday GM; Henderson J; Griffiths FM; Heinemann T; Riederer P; Gerlach M, 2003, 'The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration', Experimental Neurology, vol. 184, pp. 530 - 535, http://dx.doi.org/10.1016/j.expneurol.2003.08.006

Gerlach M; Double KL; Ben-Shachar D; Zecca L; Youdim MBH; Riederer P, 2003, 'Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease', Neurotoxicity Research, vol. 5, pp. 35 - 43, http://dx.doi.org/10.1007/BF03033371

Halliday GM; Double KL; Macdonald V; Kril JJ, 2003, 'Identifying severely atrophic cortical subregions in Alzheimer's disease', Neurobiology of Aging, vol. 24, pp. 797 - 806, http://dx.doi.org/10.1016/S0197-4580(02)00227-0

Double KL; Rowe DB; Hayes M; Chan DKY; Blackie J; Corbett A; Joffe R; Fung VS; Morris J; Halliday GM, 2003, 'Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test', Archives of Neurology, vol. 60, pp. 545 - 549, http://dx.doi.org/10.1001/archneur.60.4.545

Gerlach M; Double KL; Reichmann H; Riederer P, 2003, 'Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson`s disease', Journal of Neural Transmission, vol. 65, pp. 167 - 183

Gerlach M; Double KL; Arzberger T; Leblhuber F; Tatschner T; Riederer P, 2003, 'Dopamine receptor agonists in current clinical use: Comparative dopamine receptor binding profiles defined in the human striatum', Journal of Neural Transmission, vol. 110, pp. 1119 - 1127

Berg D; Gerlach M; Youdim MBH; Double KL; Zecca L; Riederer P; Becker G, 2002, 'Erratum: Brain iron pathways and their relevance to Parkinson's disease (Journal of Neurochemistry (79) (225-236))', Journal of Neurochemistry, vol. 80, pp. 719, http://dx.doi.org/10.1046/j.0022-3042.2001.00742.x

Double KL; Ben-Shachar D; Youdim MBH; Zecca L; Riederer P; Gerlach M, 2002, 'Influence of neuromelanin on oxidative pathways within the human substantia nigra', Neurotoxicology and Teratology, vol. 24, pp. 621 - 628, http://dx.doi.org/10.1016/S0892-0362(02)00218-0

Riederer P; Reichmann H; Janetzky B; Sian J; Lesch KP; Lange KW; Double KL; Nagatsu T; Gerlach M, 2001, 'Neural degeneration in Parkinson's disease.', Advances in neurology, vol. 86, pp. 125 - 136

Berg D; Gerlach M; Youdim MBH; Double KL; Zecca L; Riederer P; Becker G, 2001, 'Brain iron pathways and their relevance to Parkinson's disease', Journal of Neurochemistry, vol. 79, pp. 225 - 236, http://dx.doi.org/10.1046/j.1471-4159.2001.00608.x

Double KL; Zecca L; Costi P; Mauer M; Griesinger C; Ito S; Ben-Shachar D; Bringmann G; Fariello RG; Riederer P, 2000, 'Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins', Journal of Neurochemistry, vol. 75, pp. 2583 - 2589, http://dx.doi.org/10.1046/j.1471-4159.2000.0752583.x

Gerlach M; Double KL; Youdim MB; Riederer P, 2000, 'Strategies for the protection of dopaminergic neurons against neurotoxicity', Neurotoxicity Research, vol. 2, pp. 99 - 114

Double KL; Riederer P; Gerlach M, 1999, 'Significance of neuromelanin for neurodegeneration in Parkinson's disease', Drug News and Perspectives, vol. 12, pp. 333 - 340

Double KL; Riederer PF; Gerlach M, 1999, 'Role of iron in 6-hydroxydopamine neurotoxicity.', Advances in neurology, vol. 80, pp. 287 - 296

Double KL; Riederer P; Gerlach M, 1999, 'The significance of neuromelanin for neurodegeneration in Parkinson`s disease', Drug News and Perspectives, vol. 1, pp. 8 - 12

Double KL; Maywald M; Schmittel M; Riederer P; Gerlach M, 1998, 'In vitro studies of ferritin iron release and neurotoxicity', Journal of Neurochemistry, vol. 70, pp. 2492 - 2499

Halliday GM; McRitchie DA; Macdonald V; Double KL; Trent RJ; McCusker E, 1998, 'Regional specificity of brain atrophy in Huntington's disease', Experimental Neurology, vol. 154, pp. 663 - 672, http://dx.doi.org/10.1006/exnr.1998.6919

Harasty J; Double KL; Halliday GM; Kril JJ; McRitchie DA, 1997, 'Language-associated cortical regions are proportionally larger in the female brain', Archives of Neurology, vol. 54, pp. 171 - 176, http://dx.doi.org/10.1001/archneur.1997.00550140045011

Cullen KM; Halliday GM; Double KL; Brooks WS; Creasey H; Broe GA, 1997, 'Cell loss in the nucleus basalis is related to regional cortical atrophy in Alzheimer's disease', Neuroscience, vol. 78, pp. 641 - 652, http://dx.doi.org/10.1016/S0306-4522(96)00569-6

Cullen K; Halliday GM; Double KL; Brooks WS; Creasey H; Broe T, 1997, 'Nucleus basalis cell loss is related to regional volumetric brain changes in Alzheimer's disease', Neuroscience, pp. 641 - 652

Double KL; Halliday GM; Kril JJ; Harasty JA; Cullen K; Brooks WS; Creasey H; Broe GA, 1996, 'Topography of brain atrophy during normal aging and Alzheimer's disease', Neurobiology of Aging, vol. 17, pp. 513 - 521, http://dx.doi.org/10.1016/0197-4580(96)00005-X

Double KL; Halliday GM; McRitchie DA; Reid WGJ; Hely MA; Morris JGL, 1996, 'Regional brain atrophy in idiopathic parkinson’s disease and diffuse lewy body disease', Dementia and Geriatric Cognitive Disorders, vol. 7, pp. 304 - 313, http://dx.doi.org/10.1159/000106896

Double KL; Crocker AD, 1995, 'Dopamine receptors in the substantia nigra are involved in the regulation of muscle tone', Proceedings of the National Academy of Sciences of the United States of America, vol. 92, pp. 1669 - 1673, http://dx.doi.org/10.1073/pnas.92.5.1669

Lee CY; Double KL; Crocker AD, 1995, 'Expression of stereotyped behaviour requires stimulation of nigral D1 dopamine receptors', Brain Research, vol. 681, pp. 205 - 208, http://dx.doi.org/10.1016/0006-8993(95)00263-P

Double KL; Crocker AD, 1993, 'Quantitative electromyographic changes following modification of central dopaminergic transmission', Brain Research, vol. 604, pp. 342 - 344, http://dx.doi.org/10.1016/0006-8993(93)90388-4

Double KL; Crocker AD, 1990, 'Effects of inactivation of D1 dopamine receptors on stereotypic and thermic responses to quinpirole (LY 171555)', Neuroscience Letters, vol. 115, pp. 81 - 85, http://dx.doi.org/10.1016/0304-3940(90)90521-A

Double KL; Crocker AD, 1990, 'Effects of selective inactivation of D1 and D2 dopamine receptors on stereotypic and hypothermic responses to quinpirole (LY 171555)', European Journal of Pharmacology, vol. 183, pp. 1424 - 1425, http://dx.doi.org/10.1016/0014-2999(90)94557-E

Shiromani PJ; Overstreet DH; Lucero S; Double KL; Jeong DU, 1990, 'Dietary lithium blunts oxotremorine-induced hypothermia in a genetic animal model of depression', Lithium, vol. 1, pp. 186 - 189

Murphy KE; Double KL; Halliday GM, 2006, 'Differential expression of tyrosine hydroxylase isoforms in human substantia nigra', in Proceedings of Aust Neuroscience Society, 26th Annual meeting of the Australian Neuroscience Society, Sydney, pp. 51 - 51, presented at 26th Annual meeting of the Australian Neuroscience Society, Sydney, 31 January - 03 February 2006

Double KL; Halliday GM, 2006, 'Do changes in neuromelanin pigment in Parkinson`s disease provide clues to the aetiology of this disorder', in Proceedings of Aust Neuroscience Society, 26th Annual meeting of the Australian Neuroscience Society, Sydney, pp. 42 - 42, presented at 26th Annual meeting of the Australian Neuroscience Society, Sydney, 31 January - 03 February 2006

Sutherland GT; Mellick GD; Double KL; Stevens J; Lee L; Rowe DB; Silburn PA; Halliday GM, 2006, 'An association between a tyrosine hydroxylase polymorphism and Parkinson`s disease', in Proceedings of Aust Neuroscience Society, 26th Annual meeting of the Australian Neuroscience Society, Sydney, pp. 52 - 52, presented at 26th Annual meeting of the Australian Neuroscience Society, Sydney, 31 January - 03 February 2006

Double KL; Li J; Scheller C; Koutsilieri E; Griffiths F; Beart PM; Mercer L; Halliday GM; Kettle E; Rowe DB, 2005, 'Functional effects of neuromelanin on neuronal and glial cells in vitro', in Proceedings of Aust Neuroscience Society, 25th Annual Meeting of the Australian Neuroscience Society, Perth, WA, pp. 38 - 38, presented at 25th Annual Meeting of the Australian Neuroscience Society, Perth, WA, 30 January - 02 February 2005

Griffiths F; Mercer L; Beart PM; Halliday GM; Riederer P; Gerlach M; Double KL, 2005, 'Morphological effects of neuromelanin and dopamine melanin on primary cell cultures', in Proceedings of Aust Neuroscience Society, 25th Annual Meeting of the Australian Neuroscience Society, Perth, WA, pp. 139 - 139, presented at 25th Annual Meeting of the Australian Neuroscience Society, Perth, WA, 30 January - 02 February 2005

Double KL; Halliday GM, 2005, 'New face of melanin', in Parkinsonism and Related Disorders, Elsevier Sci Ltd, Berlin, Germany, pp. 65 - 65, presented at 16th International Congress on Parkinson`s Disease and Related Disorders, Berlin, Germany, 05 - 09 June 2005

Double KL; Li J; Scheller C; Koutsilieri E; Griffiths F; Beart PM; Mercer L; Halliday GM; Kettle E; Rowe DB, 2005, 'Functional effects of neuromelanin and synthetic melanins in model systems', in Parkinsonism and Related Disorders, Elsevier Sci Ltd, Berlin, Germany, pp. 59 - 59, presented at 16th International Congress on Parkinson`s Disease and Related Disorders, Berlin, Germany, 05 - 09 June 2005

Fedorow HS; Garner B; Pickford R; Hook JM; Kettle E; Cartwright HR; Double KL; Gerlach M; Riederer P; Halliday GM, 2005, 'Investigations of the lipid component of neuromelanin', in Parkinsonism and Related Disorders, Elsevier Sci Ltd, Berlin, Germany, pp. 58 - 58, presented at 16th International Congress on Parkinson`s Disease and Related Disorders, Berlin, Germany, 05 - 09 June 2005

Fedorow HS; Pickford R; Hook J; Double KL; Halliday GM; Gerlach M; Riederer P; Garner B, 2005, 'Dolichol is the major lipid component of neuromelanin in human substanta nigra', in Parkinsonism and Related Disorders, Elsevier Sci Ltd, Berlin, Germany, pp. 107 - 107, presented at 16th International Congress on Parkinson`s Disease and Related Disorders, Berlin, Germany, 05 - 09 June 2005

Halliday GM; Fedorow HS; Rickert C; Gerlach M; Riederer P; Double KL, 2005, 'Evidence for specific phases in the development of human neuromelanin', in Parkinsonism and Related Disorders, Elsevier Sci Ltd, Berlin, Germany, pp. 58 - 58, presented at 16th International Congress on Parkinson`s Disease and Related Disorders, Berlin, Germany, 05 - 09 June 2005

Li J; Double KL; Gerlach M; Riederer P; Gr nblatt E, 2005, 'The main effects of neuromelanin and synthetic dopamine melanin on oxidative stress related gene expression in cell lines', in Parkinsonism and Related Disorders, Elsevier Sci Ltd, Berlin, Germany, pp. 107 - 107, presented at 16th International Congress on Parkinson`s Disease and Related Disorders, Berlin, Germany, 05 - 09 June 2005

Stevens J; Sutherland GR; Lee L; Double KL; Rowe DB; Halliday GM, 2005, 'Lack of association between a functional polymorphism in the tyrosine hydroxylase gene and Parkinson`s disease', in Journal of the Neurological Sciences, Elsevier Science BV, Sydney, pp. S158 - S158, presented at XVIIIth World Congress of Neurology, Sydney, 05 - 11 November 2005

Fedorow HS; Pickford R; Hook JM; Double KL; Halliday GM; Gerlach M; Riederer P; Garner B, 2005, 'Identification of the major lipid component of neuromelanin in human dopamine neurons', in Proceedings of Aust Neuroscience Society, 25th Annual Meeting of the Australian Neuroscience Society, Perth, WA, pp. 139 - 139, presented at 25th Annual Meeting of the Australian Neuroscience Society, Perth, WA, 30 January - 02 February 2005

Potts HS; Halliday GM; Cartwright M; Rickert C; Gerlach M; Riederer P; Double KL, 2004, 'The development of nigral neuromelanin in human dopamine neurons', in Proceedings of Aust Neuroscience Society, 24th Annual Meeting of the Australian Neuroscience Society, Melbourne Convention Centre, pp. 150 - 150, presented at 24th Annual Meeting of the Australian Neuroscience Society, Melbourne Convention Centre, 27 - 30 January 2004

Fedorow HS; Double KL; Kettle E; Cartwright M; Griffiths F; Halliday GM, 2003, 'Neuromelanin in the substantia nigra has a significant lipid component', in Proceedings of Aust Neuroscience Society, 23rd Annual Meeting of the Australian Neuroscience Society, Adelaide, Sth Aust, pp. 381 - 381, presented at 23rd Annual Meeting of the Australian Neuroscience Society, Adelaide, Sth Aust, 28 - 31 January 2003

Ophof A; Double KL; Cartwright M; Halliday GM, 2003, 'Density of neuromelanin-pigment and pigment-associated alpha-synuclein in Parkinson`s disease', in Proceedings of Aust Neuroscience Society, 23rd Annual Meeting of the Australian Neuroscience Society, Adelaide, Sth Aust, pp. 370 - 370, presented at 23rd Annual Meeting of the Australian Neuroscience Society, Adelaide, Sth Aust, 28 - 31 January 2003

Double KL; Halliday GM; Henderson JM; Griffiths F, 2003, 'The dopamine induced receptor lisuride attenuates iron-mediated dopaminergic neurodegeneration', in Proceedings of Aust Neuroscience Society, 23rd Annual Meeting of the Australian Neuroscience Society, Adelaide, Sth Aust, pp. 371 - 371, presented at 23rd Annual Meeting of the Australian Neuroscience Society, Adelaide, Sth Aust, 28 - 31 January 2003

Double KL; Gerlach M; Schunemann V; Trautwein AX; Zecca L; Gallorini M; Youdim MB; Riederer P; Ben-Shachar D, 2003, 'Iron binding characteristics of neuromelanin of the human substantia nigra', in Proceedings of Aust Neuroscience Society, 23rd Annual Meeting of the Australian Neuroscience Society, Adelaide, Sth Aust, pp. 904 - 0904, presented at 23rd Annual Meeting of the Australian Neuroscience Society, Adelaide, Sth Aust, 28 - 31 January 2003

Double KL; Halliday GM; Rowe DB; Henderson JM; Riederer P; Gerlach M, 2002, 'The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration', in Movement Disorders, Wiley-Liss, Miami, Florida, USA, pp. 50 - 50, presented at 7th International Congress of Parkinson`s Disease and Movement Disorders Society Annual General Meeting, Miami, Florida, USA, 10 - 14 November 2002

Double KL; Rowe DB; Halliday GM; Riederer P; Gerlach M, 2002, 'A biochemical marker for central dopaminergic cell loss', in Movement Disorders, Wiley-Liss, Miami, Florida, USA, pp. 67 - 67, presented at 7th International Congress of Parkinson`s Disease and Movement Disorders Society Annual General Meeting, Miami, Florida, USA, 10 - 14 November 2002

Double KL; Rowe DB; Halliday GM, 2002, 'Diagnosing preclinical Parkinson`s disease: The Sydney DEDCEL study', in Proceedings of Aust Neuroscience Society, 22nd Annual meeting of the Australian Neuroscience Society, Darling Harbour, Sydney, pp. 132 - 132, presented at 22nd Annual meeting of the Australian Neuroscience Society, Darling Harbour, Sydney, 04 - 06 February 2002

Griffiths F; Double KL; Rowe DB, 2002, 'The effect of human and synthetic neuromelanin on neuronal and glial cell lines', in Proceedings of Aust Neuroscience Society, 22nd Annual meeting of the Australian Neuroscience Society, Darling Harbour, Sydney, pp. 133 - 133, presented at 22nd Annual meeting of the Australian Neuroscience Society, Darling Harbour, Sydney, 04 - 06 February 2002

Double KL; Halliday GM; Henderson JM; Griffiths F; Heinemann T; Riederer P; Gerlach M, 2002, 'The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration', in Australian Health and Medical Research Congress, Australian Health and Medical Research Congress 2002, Melbourne Convention Centre, pp. 2649 - 2649, presented at Australian Health and Medical Research Congress 2002, Melbourne Convention Centre, 24 - 29 November 2002

Double KL; Rowe DB; Griffiths F; Chan DK; Riederer P; Gerlach M, 2001, 'A specific immune response in Parkinson`s disease indicates central dopaminergic cell death.', in Proceedings of Aust Neuroscience Society, 21st Annual Meeting of the Australian Neuroscience Society, Brisbane, Qld, pp. 125 - 125, presented at 21st Annual Meeting of the Australian Neuroscience Society, Brisbane, Qld, 28 - 31 January 2001

Macdonald V; Halliday GM; Mcritchie DA; Double KL; Mccusker E, 1998, 'Brain atrophy in Huntington`s disease', in Pilowsky P (ed.), 18th Annual Meeting of the Australian Neuroscience Society, 18th Annual meeting Australian Neuroscience Society, Canberra, pp. 203, presented at 18th Annual meeting Australian Neuroscience Society, Canberra, 27 - 30 January 1998

Kril J; Halliday GM; Double KL; Harding AJ, 1997, 'Patterns of neuropathology in Alzheimer's disease and ageing', in Satellite Meeting of the 16th Congress of the International Association of Gerontology, Satellite Meeting of the 16th Congress of the International Association of Gerontology, Honolulu, Hawaii, pp. 48 - 49, presented at Satellite Meeting of the 16th Congress of the International Association of Gerontology, Honolulu, Hawaii, 16 - 18 August 1997

Double KL; Halliday GM; Kril J, 1997, 'Temporal and frontal lobe atrophy characterises Alzheimer's disease', in Brain Pathology, Int Society Neuropathology, Perth, WA, pp. 1201 - 1201, presented at XIIIth International Congress of Neuropathology, Perth, WA, 07 - 12 September 1997

Double KL; Halliday GM; Kril J, 1997, 'Temporal and frontal lobe atrophy characterises Alzheimer's disease', in Journal of Clinical Neuroscience, Churchill Livingstone, Sydney, pp. 393 - 394, presented at Australian Association of Neurologists Annual Scientific Meeting 1997, Sydney, 30 April - 02 May 1997

Ng KY; Hayes M; Mercer S; Garner B; Halliday GM; Carew-Jones F; Double KL, 2008, 'Cholesterol in Parkinson`s disease', Parkinson's Australia National Conference, Sydney, presented at Parkinson's Australia National Conference, Sydney, 16 - 17 October 2008

Double KL, 2008, 'Brain cell death in Parkinson`s disease', Parkinson's Australia National Conference, Sydney, presented at Parkinson's Australia National Conference, Sydney, 16 - 17 October 2008